The continued successful development and approval of new targeted biotech drugs for life-threatening diseases like cancer has been a real boon for patients. But these medical advances often work for only a small subset of patients, and they don't come cheap. Yet prices for these new targeted therapies are sky-high with no letup in sight, which begs the question: Who pays and for how long?
In December, President Bush moved Michael Leavitt, his Environmental Protection Agency chief, over to run the U.S. Department of Health and Human Services. Presumably, one of Leavitt's first jobs will be to help Bush pick a new commissioner of the Food and Drug Administration. With the FDA under the gun recently for its role in monitoring drug safety in the wake of the Vioxx withdrawal, Bush's choice for a new FDA chief will draw close scrutiny.
The success or failure of new drug launches will be an early 2005 focus for investors. Two big drugs to watch here include Tysabri, the new multiple sclerosis drug from Biogen Idec and
, and Tarceva, the non-small-cell lung cancer drug marketed by
We'll get a fair share of important and market-moving clinical data in 2005. Among the stocks (and drugs) to watch: Genentech and Avastin data in non-small-cell lung cancer;
Xyotax in non-small-cell lung cancer;
and Phenserine in Alzheimer's;
Revlimid in MDS and multiple myeloma;
BAY 43-9006 in renal cell cancer;
Telcyta in ovarian and lung cancer;
Ranexa in angina; and possibly
blood substitute Polyheme.
The following companies are among those with important FDA approval decisions on the docket for 2005:
American Pharmaceutical Partners